Literature DB >> 25477585

Dapagliflozin.

Dennis J Cada1, Terri L Levien2, Danial E Baker3.   

Abstract

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are sent in print and are also available on-line. Monographs can be customized to meet the needs of a facility. A drug class review is now published monthly with The Formulary Monograph Service. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, call The Formulary at 800-322-4349. The July 2014 monograph topics are albiglutide, ramucirumab, short ragweed pollen allergen extract, timothy grass pollen allergen extract, and isavuconazole. The DUE/MUE is on albiglutide.

Entities:  

Year:  2014        PMID: 25477585      PMCID: PMC4252236          DOI: 10.1310/hpj4907-647

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN: 0018-5787


  34 in total

1.  Dapagliflozin monotherapy in drug-naïve patients with diabetes: a randomized-controlled trial of low-dose range.

Authors:  C J Bailey; N Iqbal; C T'joen; J F List
Journal:  Diabetes Obes Metab       Date:  2012-07-24       Impact factor: 6.577

2.  Standards of medical care in diabetes--2014.

Authors: 
Journal:  Diabetes Care       Date:  2014-01       Impact factor: 19.112

3.  Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin.

Authors:  Kristina M Johnsson; Agata Ptaszynska; Bridget Schmitz; Jennifer Sugg; Shamik J Parikh; James F List
Journal:  J Diabetes Complications       Date:  2013-06-24       Impact factor: 2.852

4.  Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin.

Authors:  J Bolinder; Ö Ljunggren; L Johansson; J Wilding; A M Langkilde; C D Sjöström; J Sugg; S Parikh
Journal:  Diabetes Obes Metab       Date:  2013-08-29       Impact factor: 6.577

5.  Effects of rifampin and mefenamic acid on the pharmacokinetics and pharmacodynamics of dapagliflozin.

Authors:  S Kasichayanula; X Liu; S C Griffen; F P Lacreta; D W Boulton
Journal:  Diabetes Obes Metab       Date:  2012-11-19       Impact factor: 6.577

6.  Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial.

Authors:  Ele Ferrannini; Silvia Jimenez Ramos; Afshin Salsali; Weihua Tang; James F List
Journal:  Diabetes Care       Date:  2010-06-21       Impact factor: 19.112

7.  Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years.

Authors:  J P H Wilding; V Woo; K Rohwedder; J Sugg; S Parikh
Journal:  Diabetes Obes Metab       Date:  2013-08-29       Impact factor: 6.577

8.  Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects.

Authors:  B Komoroski; N Vachharajani; D Boulton; D Kornhauser; M Geraldes; L Li; M Pfister
Journal:  Clin Pharmacol Ther       Date:  2009-01-07       Impact factor: 6.875

9.  Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial.

Authors:  K Kaku; S Inoue; O Matsuoka; A Kiyosue; H Azuma; N Hayashi; T Tokudome; A M Langkilde; S Parikh
Journal:  Diabetes Obes Metab       Date:  2013-01-25       Impact factor: 6.577

10.  Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial.

Authors:  Michael A Nauck; Stefano Del Prato; Juris J Meier; Santiago Durán-García; Katja Rohwedder; Martina Elze; Shamik J Parikh
Journal:  Diabetes Care       Date:  2011-08-04       Impact factor: 19.112

View more
  1 in total

Review 1.  Sodium-glucose cotransporter-2 inhibitors: Understanding the mechanisms for therapeutic promise and persisting risks.

Authors:  Rachel J Perry; Gerald I Shulman
Journal:  J Biol Chem       Date:  2020-08-12       Impact factor: 5.157

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.